Aripiprazole Prevents From Development of Vincristine-Induced Neuropathic Nociception by Limiting Neural Nos Overexpression and Nf-Kb Hyperactivation

Aripiprazole Prevents From Development of Vincristine-Induced Neuropathic Nociception by Limiting Neural Nos Overexpression and Nf-Kb Hyperactivation Publisher Pubmed

Khalilzadeh M¹ ; Hassanzadeh F¹ ; Aghamiri H² ; Dehpour AR^{1, 3} ; Shafaroodi H^{3, 4}

Show Affiliations

1. Brain and Spinal Cord Injury Research Center, Neuroscience Institute Tehran University of Medical Sciences, Tehran, Iran
2. Department of Pharmacology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
3. Experimental Medicine Research Center, Tehran University of Medical Sciences, P.O. Box 13145-784, Tehran, Iran
4. Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, P.O. Box 13145-784, Tehran, Iran

Source: Cancer Chemotherapy and Pharmacology Published:2020

Abstract

Purpose: Increased nitric oxide (NO) synthesis and NF-kB activation have been shown as critical players in the pathophysiology of vincristine-induced peripheral neuropathy. Consistently, neural nitric oxide synthase (nNOS) inhibitors alleviated the neuropathic pain. Previous studies demonstrated that aripiprazole is capable of modulating NO synthesis and also has been reported its modulatory effect on NF-kB activity. Methods: Aripiprazole was administered daily to the male Wistar rats at the same time with establishing neuropathic model by I.P. injection of vincristine every 2 days, over 2 weeks. Efficacy of aripiprazole in suppressing the development of neuropathy was evaluated by assessing changes in body weight, mechanical threshold, withdrawal latency, sciatic nerve conduction velocity (SNCV), and compound motor action potential (CMAP) characteristics. Expression of nNOS and NF-kB activation were evaluated by western blotting Results: Rats receiving aripiprazole during neuropathy establishment period demonstrated a normal weight gain pattern, a significantly higher mechanical withdrawal threshold, and SNCV compared to vincristine-treated group. Furthermore, the amplitude and area of CMAP were significantly higher in aripiprazole group. Western blotting demonstrated a significantly reduced expression of nNOS and NF-kB activation in dorsal root ganglia of aripiprazole co-treated rats. Conclusion: In conclusion, aripiprazole effectively prevents from vincristine-induced neuropathy by limiting nNOS overexpression and NF-kB hyperactivation. © 2020, Springer-Verlag GmbH Germany, part of Springer Nature.

Related Docs

View other Related Docs

1. The Protective Effects of Sumatriptan on Vincristine - Induced Peripheral Neuropathy in a Rat Model, NeuroToxicology (2018)

2. Protective Effects of Glatiramer Acetate Against Paclitaxel-Induced Peripheral Neuropathy in Rats: A Role for Inflammatory Cytokines and Oxidative Stress, Neurochemical Research (2024)

3. Aripiprazole Improves Spinal Cord Injury in Rats: Involvement of Inflammatory Pathways, Acta Medica Iranica (2022)

4. Dapsone Improves the Vincristine-Induced Neuropathic Nociception by Modulating Neuroinflammation and Oxidative Stress, DARU# Journal of Pharmaceutical Sciences (2022)

5. Toxoplasma Gondii Infection Promotes Neuroinflammation Through Cytokine Networks and Induced Hyperalgesia in Balb/C Mice, Inflammation (2016)

6. Protective Effects of Sumatriptan on Ischaemia/Reperfusion Injury Following Torsion/Detorsion in Ipsilateral and Contralateral Testes of Rat, Andrologia (2019)

7. Atorvastatin Prevents the Development of Diabetic Neuropathic Nociception by Possible Involvement of Nitrergic System, Journal of Applied Biomedicine (2021)

8. Assessment of Sumatriptan on Sepsis-Induced Kidney Injury in the Cecal Ligation and Puncture Mice Model, Drug Research (2021)

Experts (# of related papers)

View all Related Experts

Ahmad Reza Dehpour (8)

Alireza Abdollahi (3)

Style	Citing Format
MLA	Khalilzadeh M, et al.. "Aripiprazole Prevents From Development of Vincristine-Induced Neuropathic Nociception by Limiting Neural Nos Overexpression and Nf-Kb Hyperactivation." Cancer Chemotherapy and Pharmacology, vol. 86, no. 3, 2020, pp. 393-404.
APA	Khalilzadeh M, Hassanzadeh F, Aghamiri H, Dehpour AR, Shafaroodi H (2020). Aripiprazole Prevents From Development of Vincristine-Induced Neuropathic Nociception by Limiting Neural Nos Overexpression and Nf-Kb Hyperactivation. Cancer Chemotherapy and Pharmacology, 86(3), 393-404.
Chicago	Khalilzadeh M, Hassanzadeh F, Aghamiri H, Dehpour AR, Shafaroodi H. "Aripiprazole Prevents From Development of Vincristine-Induced Neuropathic Nociception by Limiting Neural Nos Overexpression and Nf-Kb Hyperactivation." Cancer Chemotherapy and Pharmacology 86, no. 3 (2020): 393-404.
Harvard	Khalilzadeh M et al. (2020) 'Aripiprazole Prevents From Development of Vincristine-Induced Neuropathic Nociception by Limiting Neural Nos Overexpression and Nf-Kb Hyperactivation', Cancer Chemotherapy and Pharmacology, 86(3), pp. 393-404.
Vancouver	Khalilzadeh M, Hassanzadeh F, Aghamiri H, Dehpour AR, Shafaroodi H. Aripiprazole Prevents From Development of Vincristine-Induced Neuropathic Nociception by Limiting Neural Nos Overexpression and Nf-Kb Hyperactivation. Cancer Chemotherapy and Pharmacology. 2020;86(3):393-404.
BibTex	@article{ author = {Khalilzadeh M and Hassanzadeh F and Aghamiri H and Dehpour AR and Shafaroodi H}, title = {Aripiprazole Prevents From Development of Vincristine-Induced Neuropathic Nociception by Limiting Neural Nos Overexpression and Nf-Kb Hyperactivation}, journal = {Cancer Chemotherapy and Pharmacology}, volume = {86}, number = {3}, pages = {393-404}, year = {2020} }
RIS	TY - JOUR AU - Khalilzadeh M AU - Hassanzadeh F AU - Aghamiri H AU - Dehpour AR AU - Shafaroodi H TI - Aripiprazole Prevents From Development of Vincristine-Induced Neuropathic Nociception by Limiting Neural Nos Overexpression and Nf-Kb Hyperactivation JO - Cancer Chemotherapy and Pharmacology VL - 86 IS - 3 SP - 393 EP - 404 PY - 2020 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract